AFFYMETRIX GRANTS EPIGENOMICS NONEXCLUSIVE ACCESS TO ITS MICRO ARRAY TECHNOLOGY

June 28, 2006

Tuesday, Affymetrix Inc. said that it granted Epigenomics AG non-exclusive access to its microarray technology to develop and market microarray-based in-vitro diagnostic or IVD tests for oncology and other indications.
Trading Markets Live

KEYWORDS FDAnews Device Daily Bulletin

U.S. Government Inks $3.2 Billion Contract With Pfizer-BioNTech for Vaccine Booster Campaign

AFFYMETRIX GRANTS EPIGENOMICS NONEXCLUSIVE ACCESS TO ITS MICRO ARRAY TECHNOLOGY

Upcoming Events

FDA Ad and Promo Enforcement Trends: Past, Present and Future

EU-MDR’s Growing Pains: Are You Current with the Latest Developments?

Is Your Product a Drug or Device — and Does It Matter?: A Recent Appeals Court Decision Says It Does

Medical Device Cybersecurity: Understand the Latest Developments

Pharmaceutical Process Validation: Best Practices for Success

Gene & Cell Therapy Regulation: Comparability and Other New Developments

Featured Products

FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

FDA Provides Update on GE Healthcare’s Recall of Its Carescape R860 Ventilators

Gilead Resubmits NDA for Lenacapavir Following Complete Response Letter

FDA Warns Baby Neck Floats Used in Water Therapy Can Cause Death or Injury

U.S. Government Inks $3.2 Billion Contract With Pfizer-BioNTech for Vaccine Booster Campaign

The Revised ICH E8: A Guide to New Clinical Trial Requirements